CAPR Capricor Therapeutics, Inc.
Legal ·
Defendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026.
Capricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026.
Capricor Therapeutics, Inc. is a biotechnology company focused on developing and potentially commercializing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need. Its lead product candidate, Deramiocel, is a cell therapy made of cardiosphere-derived cells (CDCs), a population of cardiac-derived stromal cells isolated from qualified donated human hearts. The company says Deramiocel is designed to slow disease progression through immunomodulatory, anti-inflammatory, pro-angiogenic and anti-fibrotic activities, which are mediated in part by exosomes secreted by CDCs. Its Biologics License Application for Deramiocel is under review by the FDA, with a PDUFA target action date of August 22, 2026. The company has no products approved for commercial sale. Its clinical development has focused primarily on adolescents and young adults with DMD, many of whom are non-ambulatory. Its exosome platform, StealthX, is being explored for infectious diseases, monogenic diseases and other potential indications, supported by collaborations with the NIH, NIAID, Johns Hopkins University, the Department of Defense, the U.S. Army Institute of Surgical Research and Cedars-Sinai Medical Center. Nippon Shinyaku is the exclusive distributor for DMD in the United States and Japan.
| Product or program | What it is | Stage |
|---|---|---|
| Deramiocel | Cell therapy of cardiosphere-derived cells for Duchenne muscular dystrophy | BLA under FDA review; PDUFA target action date August 22, 2026 |
| StealthX exosome platform | Exosome-based therapeutics and vaccines platform under exploration |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $22.3 million |
| Research and development | $84.5 million | $50.0 million |
| Net income (loss) | -$105.0 million | -$40.5 million |
| Cash from operations | -$69.8 million | -$40.0 million |
| Cash and equivalents | $287.8 million | $11.3 million |
| Short-term investments | $30.3 million | $140.2 million |
Our latest story on this, dated Aug 14, 2026: "Capricor discloses new securities class action and derivative suit as FDA date slips". The story links the filing or release it is based on. Read the story.
Capricor Therapeutics, Inc. trades under the ticker CAPR on NASDAQ.
Capricor Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:4LN2; FWB:4LN2; GETTEX:4LN2; HAM:4LN2; HAN:4LN2; LS:A2PLU4; SWB:4LN2; TRADEGATE:4LN2; XETR:4LN2.
The SEC Central Index Key (CIK) for Capricor Therapeutics, Inc. is 1133869. Its filings are on SEC EDGAR.
58,138,989 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Capricor Therapeutics, Inc. under United States.
Our directory classifies Capricor Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Capricor Therapeutics, Inc. is US14070B3096.
aibio.space lists Capricor Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Capricor Therapeutics, Inc. is a biotechnology company focused on developing and potentially commercializing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need. Its lead product candidate, Deramiocel, is a cell therapy made of cardiosphere-derived cells (CDCs), a population of cardiac-derived stromal cells isolated from qualified donated human hearts.
Deramiocel: Cell therapy of cardiosphere-derived cells for Duchenne muscular dystrophy Stage: BLA under FDA review; PDUFA target action date August 22, 2026.
StealthX exosome platform: Exosome-based therapeutics and vaccines platform under exploration
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Capricor Therapeutics, Inc. reported a net loss of $105.0 million for the fiscal year ended Dec 31, 2025, and used $69.8 million of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio